细胞疗法成焦点，多款产品申报商保和基本医保

Group 1 - The National Healthcare Security Administration has announced the preliminary review list for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, highlighting CAR-T therapies as a focal point [1] - Among the seven CAR-T products that have been launched, five are applying for the commercial insurance innovative drug catalog, while three are simultaneously pushing for inclusion in the basic medical insurance [1] - The commercial insurance innovative drug catalog covers a wide range of rare disease medications, cell and gene therapies, and advanced tumor immunotherapies, indicating a shift in the competitive landscape of the industry [1] Group 2 - The commercial insurance innovative drug catalog aims to include drugs that are not yet eligible for the medical insurance catalog but possess high innovation and clinical value [1] - This initiative is seen as a crucial step in building a multi-tiered medical security system, allowing more high-value innovative drugs to enter the payment system earlier, alleviating short-term pressure on medical insurance funds [1] - Companies involved in cell therapy concepts listed on the A-share market include Chengda Pharmaceutical and Guanhao Biological [1]